Unified IP classification: Patent/FTO + ChEMBL max_phase + ClinicalTrials.gov + Expression + CDx biomarker matching. Routes each hero to optimal development pathway.
Approved drug scaffolds exist. Modify for selectivity, skip de novo generation entirely.
→ Run expression matching (TCGA) → Analog design → Direct to synthesis
⏱️ Timeline: 6-12 months to IND candidate
✅ ALL 31 VALIDATED — TCGA expression confirmed in target cancer
Top candidates: loading...
| Gene | Cancer | Phase | TCGA Score | Evidence |
|---|---|---|---|---|
| NTRK1 | Lung | 4 | 1.00 | Mutated in TCGA-LUAD |
| TOP1 | Colorectal | 4 | 1.00 | Mutated in TCGA-COAD |
| BCL2 | Pancreatic | 4 | 1.00 | Mutated in TCGA-PAAD |
| DDR2 | Lung | 4 | 1.00 | Mutated in TCGA-LUAD |
| MUC16 | Lung | 4 | 1.00 | Mutated in TCGA-LUAD |
| ANGPT2 | Prostate | 4 | 1.00 | Mutated in TCGA-PRAD |
| TYMS | Colorectal | 4 | 0.30 | Found in TCGA-COAD mutated genes |
| PARP1 | Lung | 4 | 0.53 | Found in TCGA-LUAD mutated genes |
| EGFR | Lung | 4 | 0.34 | Found in TCGA-LUAD mutated genes |
| KRAS | Lung | 4 | 0.43 | Found in TCGA-LUAD mutated genes |
Strong clinical trial presence. Build biomarker-drug response panels for companion diagnostics.
→ Validate biomarker-drug pairs → Build CDx panel → License to diagnostics companies
⏱️ Revenue: CDx licensing within 12-18 months
✅ 10 VALIDATED drug pairs + 32 PATHWAY-INFERRED signals
Top candidates: loading...
| Gene | Drug(s) | Type | Status |
|---|---|---|---|
| KRAS_CRC | cetuximab, panitumumab | Resistance | ✅ Validated |
| NRAS | cetuximab, panitumumab | Resistance | ✅ Validated |
| BRAF_CRC | encorafenib, vemurafenib | Sensitivity | ✅ Validated |
| DPYD | 5-FU, capecitabine | Toxicity | ✅ Validated |
| PIK3CA_CRC | alpelisib | Sensitivity | 🔬 Cross-cancer |
| ERBB2_CRC | trastuzumab, T-DXd | Sensitivity | 🔬 Cross-cancer |
| FGFR2_CRC | erdafitinib | Sensitivity | 🔬 Pathway |
| MSH2 | pembrolizumab | MMR deficiency | 🔬 Pathway |
| MSH6 | pembrolizumab | MMR deficiency | 🔬 Pathway |
| MLH1 | pembrolizumab | MMR deficiency | 🔬 Pathway |
| CTLA4_CRC | ipilimumab | Checkpoint | 🔬 Pathway |
| CD274_CRC | pembrolizumab | Checkpoint | 🔬 Pathway |
| CD40 | selicrelumab | Immune agonist | 🔬 Pharmacogenomic |
| CDK7 | samuraciclib | Sensitivity | 🔬 Pharmacogenomic |
Note: MSS CRC is immunotherapy-resistant. This panel identifies which patients CAN respond (MMR-d) and which need alternative strategies (RAS/BRAF pathway targeting).
Novel targets with no existing drugs. Maximum IP value but longest development timeline.
→ GPU docking → Generative chemistry → Lead optimization → Patent filing
⏱️ Timeline: 18-36 months. Highest patent value.
1-2 trials exist. Proceed only if our molecule is differentiated (better IC50, oral bioavail, different MoA).
→ Compare our compounds vs trial compounds → Score differentiation → Proceed/Park
⏱️ Decision: Run competitive analysis within 2 weeks
High structural similarity to patented compounds. Options: design around, wait for expiry, or license.
→ Quarterly patent expiry review → Design-around scaffolds → License negotiation
⏱️ Review: Next quarterly cycle. Some patents may expire within 2 years.